ARCHIVES

ODAC Recommends Fludarabine Approval for Refractory CLL

This article is from The Cancer Letter archive.

Vol. 16 No. 36 | September 21, 1990

Download PDF Visit The Full Archive

Related Articles

Tivozanib Does Not Improve OS Compared to Sorafenib

February 22, 2013

Half Of Mexican-Origin Women With Breast Cancer Diagnosed Before Age 50, Study Finds

September 24, 2010

NCI Division Directors Seek Litton Phaseout, NIH Takeover At Frederick

October 27, 1978

President Signs Supplemental Funding For NIH And FDA.

July 11, 2008

FDA Approves Taxotere For Node+ Breast Cancer

August 27, 2004

Vanderbilt Recruits Sosman To Lead Tumor Immunology.

January 18, 2002